L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases,...
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
14 mai 2024 15h19 HE
|
Meacor inc.
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
[Latest] Global mHealth Market Size/Share Worth USD 374.6 Billion by 2032 at a 17.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
14 mars 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, March 14, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “mHealth Market Size, Trends and Insights By Device Type (Cardiac Monitors,...
Medical Biomimetics Market Size is projected to reach USD 54.25 billion by 2031, growing at a CAGR of 6.5%: Straits Research
14 mars 2024 09h20 HE
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- Medical biomimetics, also known as biomimicry or bioinspired technology, is a field that creates and develops novel medical treatments,...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...